Your session is about to expire
← Back to Search
Apixaban for Medication Adherence
Phase 4
Waitlist Available
Led By Sam Schulman, MD, PhD
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights
Summary
This is a prospective, twin-center, cohort study in patients discharged from the hospital after major abdominal or pelvic cancer surgery for cancer. This study is designed to evaluate the adherence to extended deep vein thrombosis prophylaxis (DVT) with the direct oral anticoagulant apixaban on the background of historical data from the investigator's center on low-molecular-weight heparin (LMWH) substandard adherence in the same setting.
Eligible Conditions
- Prophylaxis
- Medication Adherence
- Deep Vein Thrombosis
- Cancer
- Surgery
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
At least 80% adherence
Filled prescription
Secondary outcome measures
Rate of Venous thromboembolism post prophylaxis
Other outcome measures
Rate of Clinically relevant non-major bleeding during prophylaxis
Rate of Death during prophylaxis
Rate of Major bleeding during prophylaxis
+1 moreSide effects data
From 2018 Phase 4 trial • 557 Patients • NCT018843377%
Incision site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
TOTAL KNEE REPLACEMENT (TKR)
TOTAL HIP REPLACEMENT (THR)
Trial Design
1Treatment groups
Experimental Treatment
Group I: ApixabanExperimental Treatment1 Intervention
apixaban for extended prophylaxis against VTE after discharge
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apixaban 2.5 milligram
2021
Completed Phase 4
~60
Find a Location
Who is running the clinical trial?
McMaster UniversityLead Sponsor
896 Previous Clinical Trials
2,610,177 Total Patients Enrolled
Sam Schulman, MD, PhDPrincipal InvestigatorDr.
5 Previous Clinical Trials
479 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger